Deep Venous Thrombosis in Non-severe COVID-19 Patients Hospitalized for a Neurovascular Pathology

University Hospital, Strasbourg, France30 enrolled

Overview

Severe SARS-CoV-2 infection, responsible of COVID-19, is accompanied by many venous thromboembolic events. Antithrombotic treatment is the cornerstone of management of many neurovascular diseases (NVDs) and the benefit-risk ratio is crucial to avoid hemorrhagic complications. Therefore, in non-severe COVID-19 patients affected by NVDs, the diagnostic of deep venous thrombosis (DVT) is challenging. Using bedside Doppler ultrasonography (DUS) of lower limbs, this study investigated the rates of DVT in these patients in stroke unit.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Deep Venous Thrombosis

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

* Inclusion criteria: * Age\>18 years * COVID-19 confirmed with RT-PCER and/or chest CT-scan * Acute neurovascular disease defined as transient ischemic attack or acute ischemic stroke or venous cerebral thrombosis or hemorrhagic stroke. * Exclusion criteria: * age\<18 * Other neurovascular diseases

Locations (1)

Service Unité Neurovasculaire

Strasbourg, France

Outcomes

Primary Outcomes

Number of cumulated deep venous thrombosis among the hospitalization

Time frame: Day 7 after admisssion

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.